Cellectis Stock Forecast, Price & News

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

Is Cellectis a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Cellectis stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLLS, but not buy additional shares or sell existing shares.
View analyst ratings for Cellectis or view top-rated stocks.

How has Cellectis' stock price been impacted by Coronavirus (COVID-19)?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLLS shares have decreased by 42.1% and is now trading at $6.62.
View which stocks have been most impacted by COVID-19.

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Cellectis.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) released its quarterly earnings data on Wednesday, December, 8th. The biotechnology company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by $0.02. Cellectis had a negative net margin of 188.02% and a negative trailing twelve-month return on equity of 44.64%.
View Cellectis' earnings history.

What price target have analysts set for CLLS?

7 brokerages have issued 12-month target prices for Cellectis' shares. Their forecasts range from $10.00 to $33.00. On average, they expect Cellectis' share price to reach $21.80 in the next year. This suggests a possible upside of 229.3% from the stock's current price.
View analysts' price targets for Cellectis or view top-rated stocks among Wall Street analysts.

Who are Cellectis' key executives?

Cellectis' management team includes the following people:

• André Choulika, Chief Executive Officer & Director
• Eric Dutang, Chief Financial Officer
• Philippe Duchateau, Chief Scientific Officer
• Francisco J. Esteva, Vice President-Clinical Development
• Carrie Brownstein, Chief Medical Officer

What is André Choulika's approval rating as Cellectis' CEO?

4 employees have rated Cellectis CEO André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among Cellectis' employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cellectis' key competitors?

Some companies that are related to Cellectis include Sorrento Therapeutics (SRNE), C4 Therapeutics (CCCC), REGENXBIO (RGNX), Inhibrx (INBX), Replimune Group (REPL), Molecular Partners (MOLN), Coherus BioSciences (CHRS), Vaxcyte (PCVX), Immunocore (IMCR), Sangamo Therapeutics (SGMO), Immunovant (IMVT), SOPHiA Genetics (SOPH), Century Therapeutics (IPSC), Adagio Therapeutics (ADGI) and Agenus (AGEN).
View all of CLLS's competitors.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (2.37%) and Exchange Traded Concepts LLC (0.76%).

Which major investors are buying Cellectis stock?

CLLS stock was acquired by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and Baillie Gifford & Co..

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $6.62.

How much money does Cellectis make?

Cellectis has a market capitalization of $301.06 million and generates $82.46 million in revenue each year. The biotechnology company earns $-81.07 million in net income (profit) each year or ($2.93) on an earnings per share basis.

How many employees does Cellectis have?

Cellectis employs 340 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

Where are Cellectis' headquarters?

Cellectis is headquartered at 8 RUE DE LA CROIX JARRY, PARIS I0, 75013.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at (318) 169-1600, via email at [email protected], or via fax at 33-1-81-69-16-06.